Stockreport

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise [Yahoo! Finance]

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes could improve outcomes in conditions that [Read more]